By Finance Pulse in Transformative —

J&J's Treatment Boosts Survival for Lung Cancer Patients Over Tagrisso

Johnson & Johnson's new therapy significantly extends survival in non-small cell lung cancer patients, outperforming AstraZeneca's Tagrisso by over a year.

An artistic representation of lung cancer cells with a contrasting overlay of J&J's and Tagrisso's l
J&J's Treatment Boosts Survival for Lung Cancer Patients Over Tagrisso

The study involved more than 1,000 patients with non-small cell lung cancer, showing J&J's treatment extended median overall survival by at least a year over Tagrisso.

Source